This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Ollendorf DA, Lidsky L.Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. American Journal of Therapeutics 13: 502-506, No. 6, Nov-Dec 2006
About this article
Cite this article
The true costs of administering infliximab to patients with Crohn's disease (CD) are likely to be lower in clinical practice than those reported for charged amounts,. Pharmacoecon. Outcomes News 521, 5 (2007). https://doi.org/10.2165/00151234-200705210-00013
- Public Health
- Clinical Practice
- Health Outcome
- Health Economic